TargetRx
- Biotech or pharma, therapeutic R&D
- Best-in-Class portfolio for clinical stage, includes TGRX-678 (BCR-ABL allosteric inhibitor, pivotal study, demonstrated efficacy in Asciminib-refractory CML ), TGRX-326 (3rd ALK/ROS1i, pivotal phase III study) and TGRX-1942 (next-gen RETi)
- First-in-Class degrader portfolio for TGRX-3247 (the first super-potent Pan-BCR::ABL1 oral degrader, preclinical stage) and TGRX-3544 (a highly potent and mutant-selective c-KIT degrader, preclinical stage).
- Seeking partnership for global development and commercailization.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}